9 terminated. 9 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 1 | 5 | Terminated 5 |
Follow ribociclib: new trials by email Literature Review of ribociclib trials Research Report on ribociclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib Alpelisib, Ribociclib - Breast Cancer Stage IV | Phase 2 | Terminated | UNICANCER | 4 | 2023-10-19 | 2026-10-14 |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) ARV-471, Ribociclib - Breast Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 20 | 2023-03-01 | 2026-10-27 |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 74 | 2022-10-24 | 2026-10-21 |
| Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study Abemaciclib, Anastrozole, Fulvestrant - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2019-05-31 | 2024-12-27 |
| A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy Ribociclib - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 11 | 2016-04-01 | 2020-11-05 |
| LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma LEE011, Chemoembolization - Hepatocellular Carcinoma | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 5 | 2016-04-01 | 2021-02-01 |
| Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression Enzalutamide, Ribociclib, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 52 | 2015-12-01 | 2026-04-22 |
| A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) LEE011 (ribociclib), letrozole - Early Breast Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 14 | 2013-10-01 | 2016-01-01 |
| Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. LEE011, LGX818 - Locally Advanced Metastatic BRAF Mutant Melanoma | Phase 1 / Phase 2 | Terminated | Array BioPharma | 28 | 2013-07-01 | 2016-09-13 |
Breast Neoplasms (4) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Glioma (1) · Melanoma (1) · Prostatic Neoplasms (1)
Novartis Pharmaceuticals (2) · Array BioPharma (1) · Children's Hospital Medical Center, Cincinnati (1) · M.D. Anderson Cancer Center (1) · Pfizer (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · UNICANCER (1) · University of Texas Southwestern Medical Center (1)
United States (8) · Spain (3) · Canada (2) · France (2) · Italy (2) · Singapore (2) · Australia (1) · Belgium (1) · Germany (1) · Netherlands (1) · South Korea (1)
Array BioPharma (1) · Mariko DeWire, MD (1) · Muhammad Beg, MD (1) · Senthilkumar Damodaran, MD (1) · William Kevin Kelly, MD (1)
PMID 27336726, PMID 32354716, PMID 33034839
2023 (1)